Importance Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients
with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate …

Background We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-
care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a …

Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro
and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We …

Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-
to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …

Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …

Background Remdesivir is approved by the US Food and Drug Administration for the
treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been …

Importance Clinical effectiveness data on remdesivir are urgently needed, especially among
diverse populations and in combination with other therapies. Objective To examine whether …

Background Although several therapeutic agents have been evaluated for the treatment of
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …

Purpose This review was aimed to synthesise the best available evidence on the
effectiveness and safety of remdesivir in the treatment of moderate to severe COVID-19 …